Delta-Fly Pharma, Inc. (JP:4598)
:4598
Want to see JP:4598 full AI Analyst Report?
4598 Stock Chart & Stats
¥507.00
-¥3.00(-0.55%)
At close: 4:00 PM EST
¥507.00
-¥3.00(-0.55%)
Day’s Range― - ―
52-Week Range¥184.00 - ¥793.00
Previous CloseN/A
Volume237.90K
Average Volume (3M)379.72K
Market Cap
¥2.77B
Enterprise Value¥2.17B
Total Cash (Recent Filing)¥730.32M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-171.79
Shares Outstanding13,995,000
10 Day Avg. Volume693,770
30 Day Avg. Volume379,723
Financial Highlights & Ratios
PEG Ratio1.83
Price to Book (P/B)18.22
Price to Sales (P/S)0.00
P/FCF Ratio-2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage is a durable financial strength: with virtually no debt the company faces lower interest and refinancing pressure, which conserves optionality for higher-risk R&D cycles. This structural buffer lengthens runway and reduces default risk versus highly leveraged peers.
Proprietary Drug DeliveryOwning proprietary delivery technology provides a sustainable competitive advantage in oncology: it can enhance clinical differentiation, support IP protection, and make the pipeline more attractive to partners. Such platform assets underpin licensing and long-term value creation.
Multiple Funding AvenuesA business model that can monetize via licensing, milestones, partnerships and grants reduces reliance on product sales alone. Structurally this diversifies funding sources, enabling non-dilutive capital and strategic alliances that can sustain development through regulatory milestones.
Bears Say
High Cash BurnPersistent negative operating and free cash flow is a fundamental weakness: ongoing cash burn forces frequent external financing or partnerships, increasing dilution risk and constraining long-term planning. Renewed cash burn in 2025 indicates the funding gap remains unresolved.
Shrinking Capital BaseA materially eroded equity and contracting asset base reduce financial flexibility. Over months this limits the company's ability to scale trials, invest in critical programs, or absorb development setbacks, making strategic choices and negotiation leverage weaker with partners or acquirers.
Minimal Commercial RevenueAbsence of recurring commercial revenue makes the firm's prospects binary and R&D-dependent: without product sales, losses persist and value hinges on trial and approval outcomes. This structural lack of revenue increases financing frequency and long-term execution risk.
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥184.00 and its highest was ¥793.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥2.77B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is May 15, 2026 which is in 10 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on Feb 13, 2026. The company reported -¥33.68 earnings per share for the quarter, missing the consensus estimate of N/A by -¥33.68.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 13,995,000 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥33.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.802%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.